SCHEMBL4853529

SCHEMBL4853529

Cc1ncccc1OCCc1ccc2c(c1)NC(=O)c1ccc(Cl)cc1N2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 16/20 0.46
CYP1A2 P05177 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
RAB9A P51151 1/20 0.45
MCL1 Q07820 1/20 0.45
CDK2 P24941 2/20 0.39
IRAK4 Q9NWZ3 2/20 0.39
CDC7 O00311 1/20 0.39
ROCK2 O75116 1/20 0.39
MAP4K4 O95819 1/20 0.39
GSK3B P49841 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
AURKA O14965 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4859229 0.86 CHEK1 (0.45) CHEK1CYP1A2SMN1; SMN2NPC1ALDH1A1
SCHEMBL4857292 0.85 CHEK1 (0.60) CHEK1CDK2IRAK4GSK3BAURKA
SCHEMBL4850150 0.82 CHEK1 (0.52) CHEK1CYP1A2SMN1; SMN2NPC1ALDH1A1
SCHEMBL4848723 0.82 NPC1 (0.40) CHEK1CYP1A2SMN1; SMN2NPC1ALDH1A1
SCHEMBL4858809 0.82 CHEK1 (0.60) CHEK1CDK2IRAK4ROCK2MAP4K4
SCHEMBL4855239 0.82 CHEK1 (0.44) CHEK1AURKA
SCHEMBL4857711 0.79 CHEK1 (0.62) CHEK1
SCHEMBL4849452 0.79 CHEK1 (0.63) CHEK1
SCHEMBL4856364 0.79 CHEK1 (0.65) CHEK1CYP1A2SMN1; SMN2NPC1ALDH1A1
SCHEMBL4856416 0.78 CHEK1 (0.64) CHEK1CDK2IRAK4GSK3BAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 CHEK1 38/4885CYP1A2 3589/4885SMN1; SMN2 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.